iShares Nasdaq Biotechnology (IBB)

Add to Watchlists
Create an Alert
383.81 +1.68  +0.44% NASDAQ Aug 4, 20:00 Delayed 2m USD
View Full Chart
IBB Price Chart

IBB Description

iShares Nasdaq Biotechnology is a long only equity fund managed by iShares that tracks the NASDAQ Biotechnology TR USD index and has 10.08B USD assets under management. It has an forecasted dividend yield of 0.21%, a forecasted PE ratio of 28.18, and a forecasted price to book value of 7.584. The fund has a net expense ratio of 0.48%, turns over its positions 33.00% per year, and is traded on the NASDAQ.

IBB Key Info

Expense Ratio (3-31-15) 0.48%
Assets Under Management (8-3-15) 10.08B
30-Day Average Volume (8-4-15) 1.606M
Net Asset Value (8-3-15) 382.47
Discount or Premium to NAV (8-3-15) -0.09%
Turnover Ratio (3-31-15) 33.00%

IBB Asset Allocation

Type % Net % Long % Short
Cash 0.07% 0.07% 0.00%
Stock 99.93% 99.93% 0.00%
Bond 0.00% 0.00% 0.00%
Convertible 0.00% 0.00% 0.00%
Preferred 0.00% 0.00% 0.00%
Other 0.00% 0.00% 0.00%
As of Aug. 3, 2015

IBB Region Exposure

Americas 97.13%
North America 97.13%
Latin America 0.00%
Greater Europe 2.83%
United Kingdom 2.00%
Europe Developed 0.78%
Europe Emerging 0.00%
Africa/Middle East 0.04%
Greater Asia 0.04%
Japan 0.00%
Australasia 0.00%
Asia Developed 0.00%
Asia Emerging 0.04%
Market Classification
% Developed Markets 99.96%
% Emerging Markets 0.04%
As of July 30, 2015
Region breakdown data is calculated by using the long position holdings of the portfolio.

IBB Stock Sector Exposure

Basic Materials 0.00%
Communication Services 0.00%
Consumer Cyclical 0.00%
Consumer Defensive 0.00%
Energy 0.00%
Financial Services 0.00%
Healthcare 100.0%
Industrials 0.00%
Real Estate 0.00%
Technology 0.00%
Utilities 0.00%
As of Aug. 3, 2015

IBB Stock Market Capitalization

Giant 26.99%
Large 35.60%
Medium 20.04%
Small 11.19%
Micro 6.11%
As of Aug. 3, 2015
View More Holdings

IBB Top 10 Holdings

Symbol Name % Weight Price % Chg
CELG Celgene Corp 8.67% 131.08 -0.30%
AMGN Amgen Inc 8.48% 174.80 -0.45%
GILD Gilead Sciences Inc 8.04% 118.87 -0.61%
REGN Regeneron Pharmaceuticals Inc 7.34% 580.94 +4.81%
BIIB Biogen Inc 6.16% 330.38 +1.85%
ALXN Alexion Pharmaceuticals Inc 5.10% 197.15 +0.73%
VRTX Vertex Pharmaceuticals Inc 4.03% 140.30 +2.42%
ILMN Illumina Inc 3.97% 214.31 -1.10%
BMRN Biomarin Pharmaceutical Inc 3.22% 143.78 -2.30%
MYL Mylan NV 2.87% 54.67 -0.96%
As of Aug. 3, 2015
Advertisement

IBB Basic Info

Style
Equity Style Large Cap/Growth
Broad Asset Class Sector Equity
Broad Category Equity
Prospectus Objective Specialty - Health
Fund Owner Firm Name iShares
Benchmark Index
NASDAQ Biotechnology TR USD 100.0%

IBB Manager Info

Name Tenure
Diane Hsiung 7.25 yrs
Greg Savage 7.25 yrs
Jennifer Hsui 2.67 yrs
Matthew Goff 1.51 yrs

IBB Risk Info

Beta 0.825
Max Drawdown (All) 62.85%
Historical Sharpe (10y) 1.030
Historical Sortino (All) 0.8286
30-Day Rolling Volatility 24.70%
Daily Value at Risk (VaR) 1% (All) 4.85%
Monthly Value at Risk (VaR) 1% (All) 19.62%

IBB Fundamentals

Dividend Yield TTM (8-4-15) 0.03%
Weighted Average PE Ratio 28.37
Weighted Average Price to Sales Ratio 9.815
Weighted Average Price to Book Ratio 7.916
Weighted Median ROE 10.53%
Weighted Median ROA 2.77%
Forecasted Dividend Yield 0.21%
Forecasted PE Ratio 28.18
Forecasted Price to Sales Ratio 8.626
Forecasted Price to Book Ratio 7.584
Number of Holdings 146
As of Aug. 3, 2015

IBB Growth Estimates

Forecasted 5 Yr Earnings Growth 11.90%
Forecasted Book Value Growth 13.50%
Forecasted Cash Flow Growth 28.75%
Forecasted Earnings Growth 36.72%
Forecasted Revenue Growth 14.96%
As of Aug. 3, 2015

IBB Performance

  Returns Total Returns
1M 3.63% 3.63%
3M 11.19% 11.21%
6M 22.80% 22.82%
1Y 52.26% 52.32%
3Y 189.9% 191.5%
5Y 357.7% 363.8%
As of Aug. 3, 2015

IBB Net Flows

1M 665.89M
3M 840.81M
6M 1.353B
YTD 1.315B
1Y 2.106B
3Y 2.962B
5Y 3.003B
As of July 31, 2015

IBB Attributes

Key Dates
Inception Date 2/5/2001
Last Annual Report Date 3/31/2015
Last Prospectus Date 7/31/2014
Attributes
Exchange Traded Share Yes
Exchange Traded Note No
Enhanced Index Fund No
Index Fund Yes
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan Yes
General Availability
Available for Insurance Product No
Available for Retirement Plan No
Available for RRSP No
Advertisement

You've hit the 10 page limit on YCharts.

Experience the power of YCharts.
Start your Free 7-Day Trial.

Start My Free Trial No credit card required.

Already a subscriber? Sign in.

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}
Start your free 7-Day Trial.

{{root.upsell.info.button_text}} No credit card required.

Already a subscriber? Sign in.